Compare IDEXX Laboratories, Inc. (IDXX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Kinross Gold Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Kinross Gold Corporation trades at $23.7 (market cap $27.62B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.69% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Kinross Gold Corporation for 53 Days on average.
| IDXX | KGC | |
|---|---|---|
Market Cap | $40.43B | $27.62B |
Volume | 692,164 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $38.06 |
52-Week Low | $504.70 | $22.47 |
Typical Hold Time | 46 Days | 53 Days |
Enterprise Value | $41.32B | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
